The P2X7 receptor as a new pharmacological target for retinal diseases

Biochem Pharmacol. 2022 Apr:198:114942. doi: 10.1016/j.bcp.2022.114942. Epub 2022 Feb 5.

Abstract

Purinergic ionotropic receptors, such as the P2X7 receptor, are activated by extracellular adenosine triphosphate (ATP). The P2X7 receptor is a trimeric ATP-gated cation channel and its activation results in several downstream events, including the release of proinflammatory mediators and cell damage. The P2X7 receptor has been studied as a pharmacological target for inflammatory and neuroinflammatory diseases, and preclinical studies have recently provided evidence that P2X7 receptor activation is implicated in pathophysiology of several retinal age-related diseases. These diseases are devastating conditions that have an deep impact on the quality of life of patients and on the health systems of all countries. In this review, we discuss the role of the P2X7 receptor in retinal age-related conditions such as glaucoma, age-related macular degeneration, and diabetic retinopathy. Furthermore, we focus on the pharmacological modulation of the P2X7 receptor that could have a relevant clinical impact to prevent retinal diseases.

Keywords: Age-related macular degeneration; Diabetic retinopathy; Glaucoma; Inflammation; P2X7 receptor.

Publication types

  • Review

MeSH terms

  • Adenosine Triphosphate
  • Diabetic Retinopathy* / drug therapy
  • Humans
  • Quality of Life
  • Receptors, Purinergic P2X7
  • Retinal Diseases* / drug therapy

Substances

  • Receptors, Purinergic P2X7
  • Adenosine Triphosphate